Breyanzi (lisocabtagene maraleucel), new Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene…
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
The European Commission has granted conditional marketing authorisation for…